- Correspondence
- Open access
- Published:
The abundance of the short GATA1 isoform affects megakaryocyte differentiation and leukemic predisposition in mice
Experimental Hematology & Oncology volume 13, Article number: 24 (2024)
Abstract
Transcription factor GATA1 controls the delicate balance between proliferation, differentiation and apoptosis in both the erythroid and megakaryocytic lineages. In addition to full-length GATA1, there is an GATA1 isoform, GATA1s, that lacks the amino-terminal transactivation domain. Somatic GATA1 mutations that lead to the exclusive production of GATA1s appear to be necessary and sufficient for the development of a preleukemic condition called transient myeloproliferative disorder (TMD) in Down syndrome newborns. Subsequent clonal evolution among latent TMD blasts leads to the development of acute megakaryoblastic leukemia (AMKL). We originally established transgenic mice that express only GATA1s, which exhibit hyperproliferation of immature megakaryocytes, thus mimicking human TMD; however, these mice never developed AMKL. Here, we report that transgenic mice expressing moderate levels of GATA1s, i.e., roughly comparable levels to endogenous GATA1, were prone to develop AMKL in young adults. However, when GATA1s is expressed at levels significantly exceeding that of endogenous GATA1, the development of leukemia was restrained in a dose dependent manner. If the transgenic increase of GATA1s in progenitors remains small, GATA1s supports the terminal maturation of megakaryocyte progenitors insufficiently, and consequently the progenitors persisted, leading to an increased probability for acquisition of additional genetic modifications. In contrast, more abundant GATA1s expression compensates for this maturation block, enabling megakaryocytic progenitors to fully differentiate. This study provides evidence for the clinical observation that the abundance of GATA1s correlates well with the progression to AMKL in Down syndrome.
Key points
1. The abundance of GATA1s is a strong prognostic factor of TMD for leukemia by mediating differentiation of megakaryocytes.
2. Persistent TMD blasts not undergoing differentiation are prone to leukemic transformation.
To the Editor,
GATA1 is an essential transcription factor for erythroid and megakaryocyte differentiation. GATA1 possesses two transactivation domains (TADs), which locate either in the amino (N)- or carboxyl-terminus [1]. Somatic mutations in the GATA1 gene, resulting in the production of a shorter variant lacking the N-terminal TAD (GATA1s), are known to induce transient myeloproliferative disorder (TMD) in newborns with Down syndrome [2]. Symptoms of TMD typically regress spontaneously. However, approximately 20% of Down syndrome children with a history of TMD develop genuine acute megakaryoblastic leukemia (AMKL) due to acquisition of additional genetic events [2, 3]. Recent research revealed a significant association between the level of GATA1s protein and the risk of leukemia development [4]. Nevertheless, the molecular mechanisms underlying leukemic transformation of TMD blasts remain largely unknown. Here, for the first time we generated AMKL in mice expressing exclusively GATA1s at multiple abundances.
We employed two independent transgenic mouse lines, ΔNT-H and ΔNT-M, expressing GATA1s under the regulation of G1HRD (Gata1-hematopoietic regulatory domain) [5]. In these two mouse lines, the abundance of transgene-derived mRNA in fetal livers was much higher for ΔNT-H, and comparable for ΔNT-M, than the levels of endogenous GATA1 [5]. As a control, we used a transgenic line of mice (G1HRD-G1) expressing wild-type GATA1 under G1HRD control [5]. The human (GATA1) and mouse (Gata1) genes are located on the X-chromosome. We intercrossed ΔNT-H, ΔNT-M and G1HRD-G1 transgenic male mice with heterozygous females (Gata1.05/X), harboring an allele (Gata1.05) which expresses only 5% of wild-type GATA1 [6]. We then examined Gata1-deficient male (Gata1.05/Y) embryos harboring the various GATA1-related transgenes, referred to as ΔNTR-H, ΔNTR-M, and G1R, respectively at embryonic 18.5 days (E18.5). While Gata1.05/Y embryos succumbed to lethality by E12.5 due to anemia caused by GATA1 deficiency [6], ΔNTR-H, ΔNTR-M and G1R males were born alive [5].
At E18.5, while ΔNTR-H embryos could not be discerned from wild-type littermates as previously demonstrated [7], ΔNTR-M embryos displayed mild anemia (Fig. 1A). Nevertheless, both ΔNTR-M and ΔNTR-H embryos exhibited hyperproliferation of megakaryocytes, consistent with earlier findings (Fig. 1B,C, and Supplementary Fig. 1A) [7]. In line with the findings of flow cytometry analyses, hematoxylin and eosin-stained section of fetal livers from ΔNTR-H and ΔNTR-M mice revealed the accumulation of large megakaryocytes exceeding 10 μm in diameter (Supplementary Fig. 1B). The expressions of GATA1/GATA1s mRNAs in CD41-positive megakaryocytes were approximately 19.7 and 4.7 times higher in ΔNTR-H and ΔNTR-M embryos, respectively, compared to wild-type embryos (Fig. 1D). Therefore, hyperproliferation of megakaryocytes appears to be a consequence of the exclusive expression of GATA1s, and this situation remains unmitigated despite the excessive expression of GATA1s.
Kaplan-Meier analysis (Fig. 1E) revealed that ΔNTR-M mice showed significant early mortality compared with ΔNTR-H and G1R mice. Intriguingly, the early mortality of ΔNTR-M mice was partially and completely restrained by the additional presence of either ΔNT-M or ΔNT-H transgene, respectively. For these rescued mice, we designated Gata1.05/Y mice carrying two ΔNT-M transgenes in a homozygous manner as ΔNTR-MM, and Gata1.05/Y mice carrying both ΔNT-M and ΔNT-H transgenes in a heterozygous manner as ΔNTR-MH mice. Survival analyses showed significant differences (Fig. 1F). Upon necropsy of nineteen ΔNTR-M mice and one ΔNTR-MM mouse, it was discovered that all of them had severe hepato-splenomegaly (Fig. 1G). The tissue architecture of ΔNTR-M mice revealed infiltrations of aberrant mononuclear cells (Fig. 1H,I and Supplementary Fig. 2). Additionally, marked fibrosis was observed in the livers (Fig. 1I and Supplementary Fig. 2). Peripheral blood films showed the presence of aberrant blasts with cytoplasmic blebs (Fig. 1J and Supplementary Fig. 3). Flow cytometry revealed that the blasts were cKit+CD41dull (Fig. 1K). Nude mice transplanted with these blasts consistently developed leukemia that closely resembled the AKML phenotype (Supplementary Fig. 4), indicating that ΔNTR-M mice developed full-blown AMKL. Thus, the GATA1s expression level is a strong prognostic factor of TMD leading to AMKL.
Intriguingly, while the number of megakaryocytes increased in both lines (ΔNTR-H and ΔNTR-M; Fig. 1B,C), platelet counts were significantly diminished in ΔNTR-M embryos when compared to wild-type (Fig. 2A, left panel). Hematocrit value of ΔNTR-M embryos was significantly lower compared to that of wild-type embryos (Fig. 2A, right panel), which is in good agreement with the anemic appearance of ΔNTR-M embryos (Fig. 1A, left panel). In vitro proplatelet formation assays revealed that, although embryonic megakaryocytes of both ΔNTR-H and ΔNTR-M mice lost the ability to form proplatelets with long filamentous branches (Fig. 2B,C), bone marrow-derived megakaryocytes of ΔNTR-H mice were able to restore proplatelet formation, but those of ΔNTR-M mice were not (Fig. 2D). Thus, embryonic megakaryocytes exclusively expressing GATA1s retain a reduced ability to differentiate and form platelets. However, this defect can be partially compensated after birth if GATA1s is abundant. Similar phenomenon has been observed in induced pluripotent stem cells excursively expressing GATA1s in which differentiation can be altered by the level of GATA1s [8].
To date, two types of leukemias caused by abnormal GATA1 function have been documented [9]. One is erythroleukemia, which occurs in Gata1-knockdown female mice (reduced abundance) [10]. The other is AMKL due to GATA1 mutation, leading to a short form of GATA1 (i.e., GATA1s), found in Down syndrome children [2] and in mice as firstly explored here. In the cases of erythroleukemia, immature erythroid progenitors accumulate due to a combination of differentiation arrest and protection from apoptosis [10,11,12]. These unnatural erythroid progenitors accumulate cancerous changes at a high frequency, leading to the transformation of progenitors into leukemic cells [9]. In the latter cases, AMKL-type leukemogenesis arises from megakaryocytic progenitors that persist in the bone marrow without proper terminal maturation (Fig. 2E). We propose that an essential prognostic determinant of AMKL development is the expression level of GATA1s in TMD blasts, and whether that abundance is adequate to facilitate TMD blast differentiation into terminally matured megakaryocytes.
Data availability
All data generated or analyzed during this study are included in this published article and its supplementary information file.
Abbreviations
- TADs:
-
Transactivation domains
- TMD:
-
Transient myeloproliferative disorder
- AMKL:
-
Acute megakaryoblastic leukemia
- G1HRD:
-
Gata1-hematopoietic regulatory domain
- FSC:
-
Forward scatter
- SSC:
-
Side scatter
References
Kaneko H, Kobayashi E, Yamamoto M, Shimizu R. N- and C-terminal transactivation domains of GATA1 protein coordinate hematopoietic program. J Biol Chem. 2012;287:21439–49.
Yoshida K, Toki T, Okuno Y, et al. The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet. 2013;45:1293–9.
Shimizu R, Yamamoto M. Leukemogenesis in Down syndrome. In: Day S, ed. Health Problems in Down Syndrome: Rijeka, Croatia, InTech; 2015. Available at: http://www.intechopen.com/books/health-problems-in-down-syndrome/leukemogenesis-in-down-syndrome.
Kanezaki R, Toki T, Terui K, et al. Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia. Blood. 2010;116:4631–8.
Shimizu R, Takahashi S, Ohneda K, Engel JD, Yamamoto M. In vivo requirements for GATA-1 functional domains during primitive and definitive erythropoiesis. Embo J 2001;20:5250-60.
Takahashi S, Onodera K, Motohashi H, et al. Arrest in primitive erythroid cell development caused by promoter- specific disruption of the GATA-1 gene. J Biol Chem. 1997;272:12611–5.
Shimizu R, Kobayashi E, Engel JD, Yamamoto M. Induction of hyperproliferative fetal megakaryopoiesis by an N-terminally truncated GATA1 mutant. Genes Cells. 2009;14:1119–31.
Matsuo S, Nishinaka-Arai Y, Kazuki Y, et al. Pluripotent stem cell model of early hematopoiesis in Down syndrome reveals quantitative effect of short-form GATA1 protein on lineage specification. PLoS ONE. 2021;16:e0247595.
Shimizu R, Engel JD, Yamamoto M. GATA1-related leukaemias. Nat Rev Cancer. 2008;8:279–87.
Shimizu R, Kuroha T, Ohneda O, et al. Leukemogenesis caused by incapacitated GATA-1 function. Mol Cell Biol. 2004;24:10814–25.
Pan X, Minegishi N, Harigae H, et al. Identification of human GATA-2 gene distal IS exon and its expression in hematopoietic stem cell fractions. J Biochem. 2000;127:105–12.
Shimizu R, Yamamoto M. Contribution of GATA1 dysfunction to multi-step leukemogenesis. Cancer Sci. 2012;103:2039–44.
Mast KJ, Taub JW, Alonzo TA, et al. Pathologic features of Down syndrome myelodysplastic syndrome and acute myeloid leukemia: a report from the children’s Oncology Group Protocol AAML0431. Arch Pathol Lab Med. 2020;144:466–72.
Acknowledgements
We thank Ms. Aya Ashizawa and Eriko Naganuma for technical assistance. We also thank the Biomedical Research Core of Tohoku University Graduate School of Medicine for technical support.
Funding
This work was supported in part by JSPS KAKENHI (19H03555; R.S., 22K19450; M.Y. 23K07826; IH), and the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research) from AMED under Grant Number 23ama121038 (M.Y. & R.S.).
Author information
Authors and Affiliations
Contributions
D.I., A.H., I.H. and R.S carried out experiments. J.D.E., M.Y. and R.S. analyzed data and wrote the manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent to participant
All animal studies were conducted in accordance with guidelines approved by the Institutional Animal Experiment Committee of the Tohoku University.
Consent for publication
All authors approved the manuscript and the submission.
Competing interests
The authors declare no competing financial interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Ishihara, D., Hasegawa, A., Hirano, I. et al. The abundance of the short GATA1 isoform affects megakaryocyte differentiation and leukemic predisposition in mice. Exp Hematol Oncol 13, 24 (2024). https://doi.org/10.1186/s40164-024-00492-9
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s40164-024-00492-9